In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top 10 Big Pharma/Mid Pharma Immuno-Oncology Deals, 2011–15

Executive Summary

The pace of immuno-oncology dealmaking has accelerated over the past two years. A look at the top 10 deals.

You may also be interested in...



Key Trends In Immuno-Oncology Dealmaking

Big Pharma and Mid Pharma companies have signed over 200 immuno-oncology deals in the last five years, creating the most lucrative class in dealmaking, according to a recent Datamonitor Healthcare report. Bristol-Myers Squibb and Merck & Co. have led the charge, and the PD-L1/PD-1 target still dominates.

Deals In Depth: February 2020

Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.

Deals Shaping The Medical Industry, March 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.

Topics

UsernamePublicRestriction

Register

CO218085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel